Lung Non-Small Cell Carcinoma Clinical Trial
Official title:
Phase II Trial of Lung Chemoembolization
Verified date | June 2023 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor's blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Non-small cell lung cancer (any stage), with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy - Lung-dominant disease (majority of active tumor volume is in the chest) - At least 18 years old Exclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status > 2 - Oxygen saturation < 92% on room air - Forced expiratory volume in 1 second (FEV1) < 60% - No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lung nodules are all < 1 cm) - Life expectancy < 6 months - Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magnetic resonance imaging [MRI], or direct pressure measurement) - Recent pulmonary embolism (within 3 months) - Pulmonary arteriovenous malformation - Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month) - Symptomatic heart failure (American College of Cardiology [ACC]/American Heart Association [AHA] stage C or D) - Left bundle branch block (contraindication to pulmonary angiography) - Renal failure (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m^2) - Pregnancy or intent to become pregnant - Breast feeding - Altered mental status that would interfere with consent or follow-up - Platelets < 50,000 (after transfusion, if needed) - International normalized ratio (INR) > 2 (after transfusion, if needed) - Hemoglobin < 7 (after transfusion, if needed) - Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol) - Planned radioactive iodine imaging or therapy (contraindication to lipiodol) - Allergy to lipiodol or mitomycin - Allergy to iodinated contrast that cannot be treated with steroid / diphenhydramine premedication - Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, or that would affect subject safety |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Local progression free survival | Progression is determined using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. criteria, compared to the scan immediately prior to treatment of that territory, using the 2 largest measurable lesions per treated territory. Local progression-free survival will be estimated using the Kaplan-Meier method. | Time from the initial transarterial chemoembolization (TACE) treatment to progression in a completely treated territory (or touching the border of a completely treated area), or death from any cause, assessed at 6 months | |
Primary | Incidence of adverse events | Complications will be classified using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The rate of complications can be estimated with a standard error of less than 10%. Further, any complication that occurs with a 10% incidence will be observed with greater than 95% probability. | Up to 3 months after the last chemoembolization procedure | |
Secondary | Objective response rate (best response) | Evaluated on a per-treatment basis, using RECIST version 1.1 criteria. | Within 3 months of treatment | |
Secondary | Overall survival | Will be estimated using the Kaplan-Meier method. | Up to 9 months | |
Secondary | Progression-free survival | Will be estimated using the Kaplan-Meier method. | Up to 9 months | |
Secondary | Bronchial versus pulmonary artery blood supply | Percentage of treatments where target tumors were supplied by bronchial artery, non-bronchial systemic artery, or pulmonary artery, based on catheter angiography. Confidence intervals of proportions will be estimated using the equal-tailed Jeffreys prior interval. | Up to 9 months | |
Secondary | Lipiodol retention in treated tumors | Correlation between lipiodol retention and change in tumor size will be evaluated using Spearman's rank correlation coefficient (rho) and Spearman's test. | 4-6 weeks post-procedure | |
Secondary | Growth of TACE targeted lesions versus non-TACE targeted lesions | Percentage change in size (largest diameter) of the largest treated, compared to the largest untreated tumor will be evaluated using the Wilcoxon signed-rank test. | 4-6 weeks post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04989283 -
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05106374 -
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
|
||
Terminated |
NCT03707925 -
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
|
N/A | |
Active, not recruiting |
NCT04013542 -
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06427369 -
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Recruiting |
NCT04073745 -
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05830058 -
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04298606 -
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
|
Early Phase 1 | |
Recruiting |
NCT06122064 -
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
|
N/A | |
Recruiting |
NCT05802186 -
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
|
N/A | |
Recruiting |
NCT03634241 -
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
|
Phase 2 | |
Recruiting |
NCT04314401 -
National Cancer Institute "Cancer Moonshot Biobank"
|
||
Recruiting |
NCT05493566 -
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
|
Early Phase 1 | |
Suspended |
NCT05501665 -
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04061590 -
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT06225427 -
Gilteritinib for the Treatment of ALK NSCLC
|
Phase 1 | |
Withdrawn |
NCT04085081 -
Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers
|
N/A | |
Active, not recruiting |
NCT03939481 -
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
|